Benzinga · Aug 7, 2026
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.
AG
NASDAQ · AGIO
Agios Pharmaceuticals, Inc.
Healthcare · Biotechnology
$33.56
Up+$0.09 (+0.27%)
Updated Aug 15, 2026, 6:45 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.77B
- P/E ratio
- -4.27
- Dividend yield
- 0.00%
- 52-week range
- $22.24 – $46.00
- Volume
- 1.12M
- Avg. volume
- 1.17M
Price performance
AGIO price history
1M range · 21 trading sessions · Daily adjusted prices
AGIO closed at $33.56 after 21 trading sessions, down 15.27% for the selected period.
- Last close
- $33.56
- Period change
- -15.27%
- Period low
- $30.02
- Period high
- $40.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $33.10 | $33.81 | $32.48 | $33.56 | 1.12M |
| Aug 13, 2026 | $34.35 | $34.65 | $33.31 | $33.47 | 939.12K |
| Aug 12, 2026 | $32.74 | $34.31 | $32.33 | $34.21 | 1.22M |
| Aug 11, 2026 | $33.05 | $33.61 | $32.22 | $32.69 | 938.75K |
| Aug 10, 2026 | $31.87 | $33.10 | $31.71 | $32.59 | 1.07M |
| Aug 7, 2026 | $32.32 | $32.61 | $31.545 | $32.27 | 1.4M |
| Aug 6, 2026 | $31.44 | $32.57 | $31.44 | $31.95 | 1.19M |
| Aug 5, 2026 | $31.99 | $32.30 | $31.29 | $31.72 | 915.64K |
| Aug 4, 2026 | $31.04 | $31.755 | $30.23 | $31.60 | 1.07M |
| Aug 3, 2026 | $30.78 | $30.94 | $29.32 | $30.54 | 1.19M |
| Jul 31, 2026 | $33.34 | $33.34 | $29.94 | $30.02 | 2.1M |
| Jul 30, 2026 | $29.48 | $33.50 | $29.15 | $32.75 | 3.13M |
| Jul 29, 2026 | $35.83 | $36.365 | $34.865 | $35.01 | 1.16M |
| Jul 28, 2026 | $37.49 | $37.56 | $35.24 | $35.99 | 834.95K |
| Jul 27, 2026 | $37.04 | $38.74 | $36.225 | $36.97 | 992.59K |
| Jul 24, 2026 | $36.46 | $36.675 | $35.61 | $36.36 | 890.11K |
| Jul 23, 2026 | $35.135 | $36.68 | $35.09 | $36.28 | 778.07K |
| Jul 22, 2026 | $37.36 | $37.36 | $35.80 | $36.05 | 903K |
| Jul 21, 2026 | $35.80 | $39.37 | $35.63 | $37.36 | 3.4M |
| Jul 20, 2026 | $39.69 | $40.50 | $39.69 | $40.06 | 635.51K |
| Jul 17, 2026 | $38.02 | $39.745 | $38.01 | $39.61 | 773.96K |
Latest AGIO news
The latest Smart Investors Daily articles mentioning AGIO.
Stock researchCompany · Overview
AGIO research
Overview
Company profile and research snapshot.
Company profile
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $36.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | JP Morgan | Neutral | — |
| Jul 31, 2026 | Citigroup | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 21, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 31, 2026
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52
Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.
Benzinga · Jul 31, 2026
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $39.
Benzinga · Jul 30, 2026
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55
HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $52 to $55.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
